Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.57 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | FLI1 | Q01543 | 1/20 | 0.42 |
| ▸ | EWSR1 | Q01844 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468982 | 0.89 | GSK3B (0.59) | GSK3BPTPN1HAO1PLK1MMP2 | |
| SCHEMBL10415427 | 0.83 | PTPN1 (0.64) | GSK3BPTPN1HAO1PLK1 | |
| SCHEMBL205280 | 0.82 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL6302968 | 0.81 | HAO1 (0.56) | HAO1PLK1MMP2MMP9MMP8 | |
| SCHEMBL275400 | 0.81 | HAO1 (0.56) | HAO1PLK1MMP2MMP9MMP8 | |
| SCHEMBL5107175 | 0.80 | GSK3B (0.57) | GSK3BPTPN1TAS1R3TAS1R1 | |
| SCHEMBL8536860 | 0.80 | HSD17B3 (0.49) | HAO1PLK1MMP2MMP9MMP8 | |
| Methylsulfanylmethane SCHEMBL28782225 | 0.79 | GSK3B (0.88) | GSK3BPTPN1 | |
| SCHEMBL6050822 | 0.79 | GSK3B (0.57) | GSK3BHAO1PLK1MMP2MMP9 | |
| SCHEMBL9663847 | 0.79 | GSK3B (0.55) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004053-B1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2021-03-24 | — | — | EP | claimed |
| US-10112898-B2 | Process for the preparation of saroglitazar pharmaceutical salts | CADILA HEALTHCARE LIMITED (IN) | 2018-10-30 | — | — | US | claimed |
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2016-07-07 | — | — | US | claimed |
| US-20160107989-A1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2016-04-21 | — | — | US | claimed |
| EP-3004053-A2 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2016-04-13 | — | — | EP | claimed |
| WO-2015033357-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2015-03-12 | — | — | WO | claimed |
| WO-2014195967-A2 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2014-12-11 | — | — | WO | claimed |
| US-20040242680-A1 | 1-[(4-methyl thio)phenyl]-2-(phenyl acetoxy)-1-ethanone and a process for preparing the same | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2004-12-02 | — | — | US | claimed |
| WO-2003030812-A2 | 1-[(4-METHYL THIO)PHENYL]-2-(PHENYL ACETOXY)-1-ETHANONE AND A PROCESS FOR PREPARING THE SAME | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2003-04-17 | — | — | WO | claimed |
| CN-119241405-A | Elafibranor synthesis method | 武汉九州钰民医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118994063-A | Novel method for synthesizing eremophilne intermediate | 上海博悦生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-116514622-B | Method for simply synthesizing alpha-bromomethyl ketone compound | 湖南工学院 | 2024-09-27 | — | — | CN | disclosed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-0044704-A1 | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-01-27 | — | — | EP | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| US-4013692-A | ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS | RIKER LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | HPD, HMGCR, CYP51A1 | GSK3B 3068/4885PTPN1 501/4885HAO1 799/4885 |
| US-20040242680-A1 | 1-[(4-methyl thio)phenyl]-2-(phenyl acetoxy)-1-ethanone and a process for preparing the same | PTGES2, PTGS2, CYP2J2 | GSK3B 4508/4885PTPN1 2091/4885HAO1 36/4885 |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | GSK3B 52/4885PTPN1 994/4885HAO1 867/4885 |
| US-20160107989-A1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CYP51A1, DHCR7, LIPA | GSK3B 2947/4885PTPN1 1289/4885HAO1 1178/4885 |
| US-10112898-B2 | Process for the preparation of saroglitazar pharmaceutical salts | DPP4, CYP51A1, TPP1 | GSK3B 2020/4885PTPN1 1386/4885HAO1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.